November-December . 2024 | The HEALTH

This growth , estimated at a compound annual growth rate ( CAGR ) of 9.05 per cent , was primarily driven by the increasing prevalence of these vision conditions and recent advancements in treatment options .

Recent developments in the industry underscored the rising demand for effective solutions . Innovations from key players notably spurred the market ’ s growth .

In June 2022 , Johnson & Johnson launched the ACUVUE OASYS MAX 1-Day and ACUVUE OASYS MAX 1-Day MULTIFOCAL contact lenses , which provided enhanced comfort and clarity . Additionally , their TECNIS Synergy Toric II intraocular lens , known for its rotational stability , and the CATALYS System cOS 6.0 software for astigmatism management were introduced to the market .

NIDEK Co . Ltd . also made strides with its Retina Scan Duo 2 , a combined OCT and fundus camera system launched in October 2021 , which improved clinical efficiency .

Essilor made headlines with the introduction of Stellest , a new

GENSCRIPT Biotech Corporation ( GenScript ), a global leader in life sciences services and products , has announced the establishment of new operations site and logistics centre in Sydney , Australia .

This strategic expansion represents a significant milestone in GenScript ’ s continued commitment to supporting the rapid growth of the biotechnology sector in Australia .

It also underscores the company ’ s determination to strengthen GenScript ’ s presence in the Asia-Pacific region and globally , advancing innovative solutions that address the evolving needs of the industry .

The new Sydney facility will significantly enhance GenScript ’ s ability to serve customers across the region , ensuring faster and more efficient delivery of research type of spectacle lens designed to slow myopia progression in children , which received Breakthrough Device designation from the US FDA in May 2021 . Such product launches were expected to enhance market adoption and foster competitiveness among manufacturers .

The market also grappled with substantial challenges , particularly the high costs associated with many treatment options . Financial barriers posed by expensive glasses , contact lenses , and surgical procedures like LASIK and PRK have limited access for many patients . This situation was exacerbated by the need for ongoing pre-and post-operative care , which further increased the financial burden on individuals seeking vision correction .

Demographic factors contributed to the market ’ s dynamics , with elderly populations particularly impacted by age-related

reagents and products .

With a local presence , Australian researchers and biotech companies will no longer need to navigate the complexities of permit applications , customs clearance , and tax payments , streamlining the procurement process , and allowing them to focus on advancing their groundbreaking research and innovation .

A key highlight of the Sydney site is the introduction of nextday shipping for high-demand products such as off-the-shelf mRNA , growth factors , Cas proteins , and more . This expedited service ensures that researchers and biotech companies can access essential materials with unprecedented speed , accelerating their scientific discoveries and development efforts .

vision issues . Conditions such as glaucoma , cataracts , and digital eye strain from prolonged screen exposure drove demand for various treatments , including corneal inlays and implantable contact lenses . Surgical options , including conductive keratoplasty and LASEK , remained popular among those seeking permanent solutions .

Despite the challenges , advancements in technology such as telemedicine , gene therapy , and stem cell therapy were emerging trends that promised to improve access to care .

However , the high costs associated with treatments continued to pose significant obstacles , potentially hindering market growth in the coming years . As the landscape evolved , the focus on eye care remained critical , with vision impairment and eye pressure issues highlighted as major health concerns .

GenScript ’ s rotating Chief Executive Officer Sherry Shao commented on the expansion : “ Establishing a logistics hub in Sydney enables us to deliver more localised support to our Australian partners . We see this as more than just an operational expansion – it ’ s about building long-term relationships within the region ’ s biotech ecosystem .

“ By removing import barriers and offering next-day delivery on key products , we are helping our customers focus entirely on advancing their research without the logistical challenges that previously existed .”

INDONESIA recently hosted a High-Level Meeting , where leaders and experts in tuberculosis ( TB ) convened to discuss strategies , innovations , and achievements in the global fight against the disease .

The full-day session brought together a distinguished group of global stakeholders dedicated to addressing and eliminating the TB pandemic .

The meeting featured a series of expert panels that provided comprehensive analyses of the current state of TB , alongside forward-looking strategies prioritising groundbreaking solutions in treatment , diagnostics , and vaccine development .

Representing TB Alliance were President and Chief Executive Officer Dr Mel Spigelman , Senior Vice President ( R & D ) Dr Eugene Sun , and Senior Vice President ( Market Access ) Sandeep Juneja , who spoke on panels addressing the transformation of TB research and development ( R & D ) and the accelerated rollout of TB drugs worldwide .

During the High-Level Meeting , Dr Spigelman announced that TB Alliance is pioneering a transformative “ one by one ” approach to TB treatment . The goal is to treat latent TB infections in one day and to treat active TB in one month .

“ This ambitious vision aims to simplify TB care dramatically , making treatment faster and more manageable for all people with TB .”

He added that this vision , built on the latest scientific breakthroughs , offers a path forward to contribute to the elimination of TB while easing the treatment journey for millions .

Dr Eugene Sun emphasised the importance of innovation in the mission to end TB .

“ TB Alliance ’ s R & D strategy focuses on identifying and developing new cures that simplify treatment by making it shorter , easier to administer , and more effective .

“ Our objective is to save lives by advancing science . With bold , people-centred solutions , we can redefine what is possible in TB care and accelerate the end of this devastating disease .”